Affinia Therapeutics IPO

affiniatx.comHealthcare / BioTech & Pharma

Affinia Therapeutics’ was founded in 2019 by Aaron Tward, Botond Roska, Luk Vandenberghe, Rob Aboud, and Robert Johnson. Affina Therapeutics has made an S-1 public filing.

Affinia Therapeutics’ purpose is to develop gene therapies that can have a transformative impact on people affected by devastating rare and non-rare diseases and methodically engineer novel AAV vectors and regulatory elements to make gene therapies with potentially improved tissue tropism, cell specificity, safety, and yields. Per Forge data, Affinia Therapeutics has raised a total of $170 million in funding over 2 rounds. Their latest funding was raised on May 3, 2021, from a Series B round. Key investors include Farallon Capital Management, F-Prime Capital, New Enterprise Associates, and EcoR1 Capital.

These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.

Buy or sell Affinia Therapeutics stock Learn more about Affinia Therapeutics stock

Learn more about Affinia Therapeutics

Is Affinia Therapeutics a publicly traded company?

Affinia Therapeutics is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

What is Affinia Therapeutics's IPO price?

The IPO price for Affinia Therapeutics will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.

Can you invest in Affinia Therapeutics pre-IPO?

Affinia Therapeutics is privately held company and is not publicly traded, therefor investing in Affinia Therapeutics pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to invest in private companies before their potential IPO. If you are not an accredited investor, discover how to begin the the process to potentially qualify for new investment opportunities.

What is the value of my Affinia Therapeutics shares?

To determine the value of your Affinia Therapeutics shares, create a free account to gain access to Forge’s platform. Forge Markets contains pricing information for hundreds of pre-IPO companies. A Private Market Specialist will also be available to assist you with any inquiries related to your Affinia Therapeutics shares. You can also learn more about how to sell your private shares before getting started.

Can you sell Affinia Therapeutics before it goes public?

Yes, you can seek to sell shares in Affinia Therapeutics while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.

What is Affinia Therapeutics's funding to date?

Affinia Therapeutics has raised $179.09MM to date.

When was Affinia Therapeutics founded?

Affinia Therapeutics was founded in 2019.

Affinia Therapeutics funding rounds and last known valuation

Date	Funding Round	Funding Raised	Price per Share	Last Known Valuation
5/3/2021	Series B	$110MM raised	$XXX.XX	$XXX.XX
3/31/2020	Series A	$60.57MM raised	$XXX.XX	$XXX.XX
11/5/2019	Series A-1	$8.52MM raised	$XXX.XX	$XXX.XX

Based on primary financings

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.